Novel molecular approaches to the detection of heart transplant rejection

Personalized Medicine

Volumn 14, Issue 4, 2017, Pages 293-297

  Kransdorf, Evan P ^a   Kobashigawa, Jon A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antibody mediated rejection; Cellular rejection; Endomyocardial biopsy; Gene expression profiling; Genomics; Heart transplantation; Mycophenolate mofetil; Pharmacogenomics; Tacrolimus

Indexed keywords

MICRORNA; BIOLOGICAL MARKER;

CARDIAC GRAFT REJECTION; GENE EXPRESSION; HEART MUSCLE BIOPSY; HUMAN; MICROARRAY ANALYSIS; MICROSCOPE; MOLECULAR DIAGNOSIS; MOLECULAR MICROSCOPE; NOTE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; BIOPSY; CARDIAC MUSCLE; GENETICS; GRAFT REJECTION; HEART TRANSPLANTATION; METABOLISM; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; TRANSPLANTATION TOLERANCE;

BIOMARKERS; BIOPSY; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MICRORNAS; MYOCARDIUM; PRECISION MEDICINE; TRANSPLANTATION TOLERANCE;

EID: 85022206664     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme-2017-0024     Document Type: Note

References (30)

1. Lund LH, Edwards LB, Dipchand AI et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third adult heart transplantation report-2016; focus theme: Primary diagnostic indications for transplant. J. Heart Lung Transplant. 35(10), 1158-1169 (2016).
2. Kubo SH, Naftel DC, Mills RM et al. Risk factors for late recurrent rejection after heart transplantation: A multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group. J. Heart Lung Transplant. 14(3), 409-418 (1995).
3. Raichlin E, Edwards BS, Kremers WK et al. Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation. J. Heart Lung Transplant. 28(4), 320-327 (2009).
4. Söderlund C, Öhman J, Nilsson J et al. Acute cellular rejection the first year after heart transplantation and its impact on survival: A single-centre retrospective study at Skane University Hospital in Lund 1988-2010. Transpl. Int. 27(5), 482-492 (2014).
5. Hammond MEH, Revelo MP, Miller DV et al. ISHLT pathology antibody mediated rejection score correlates with increased risk of cardiovascular mortality: A retrospective validation analysis. J. Heart Lung Transplant. 35(3), 320-325 (2016).
6. Caves PK, Stinson EB, Billingham ME, Shumway NE. Serial transvenous biopsy of the transplanted human heart. Improved management of acute rejection episodes. Lancet 1(7862), 821-826 (1974).
7. Hamour IM, Burke MM, Bell AD, Panicker MG, Banerjee R, Banner NR. Limited utility of endomyocardial biopsy in the first year after heart transplantation. Transplantation 85(7), 969-974 (2008).
8. Shah KB, Flattery MP, Smallfield MC et al. Surveillance endomyocardial biopsy in the modern era produces low diagnostic yield for cardiac-allograft rejection. Transplantation 99(8), e75-e80 (2015).
9. Tang Z, Kobashigawa J, Rafiei M, Stern LK, Hamilton M. The natural history of biopsy-negative rejection after heart transplantation. J. Transplant. 2013(11), 1-6 (2013).
10. Yang H-M, Lai CK, Gjertson DW et al. Has the 2004 revision of the International Society of Heart and Lung Transplantation grading system improved the reproducibility of the diagnosis and grading of cardiac transplant rejection? Cardiovasc. Pathol. 18(4), 198-204 (2009).
11. Angelini A, Andersen CB, Bartoloni G et al. A web-based pilot study of inter-pathologist reproducibility using the ISHLT 2004 working formulation for biopsy diagnosis of cardiac-allograft rejection: The European experience. J. Heart Lung Transplant. 30(11), 1214-1220 (2011).
12. Crespo-Leiro MG, Zuckermann A, Bara C et al. Concordance among pathologists in the second Cardiac- Allograft Rejection Gene Expression Observational Study (CARGO II). Transplantation 94(11), 1172-1177 (2012).
13. ZakliczyNski M, Nozynski J, Konecka-Mrowka D et al. Quilty effect correlates with biopsy-proven acute cellular rejection but does not predict transplanted heart coronary artery vasculopathy. J. Heart Lung Transplant. 28(3), 255-259 (2009).
14. Kobashigawa JA. The future of heart transplantation. Am. J. Transplant. 12(11), 2875-2891 (2012).
15. Kransdorf EP, Kobashigawa JA. Genetic and genomic approaches to the detection of heart transplant rejection. Per. Med. 9(7), 693-705 (2012).
16. Mohan R, Kobashigawa J. Detecting rejection in cardiac transplantation: Applications of genomic medicine. Per. Med. 13(3), 257-264 (2016).
17. Anglicheau D, Muthukumar T, Suthanthiran M. MicroRNAs: Small RNAs with big effects. Transplantation 90(2), 105-112 (2010).
18. Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. J. Am. Coll. Cardiol. 68(23), 2577-2584 (2016).
19. Sukma Dewi I, Torngren K, Gidlöf O, Kornhall B, Öhman J. Altered serum miRNA profiles during acute rejection after heart transplantation: Potential for non-invasive allograft surveillance. J. Heart Lung Transplant. 32(4), 463-466 (2013).
20. Sukma Dewi I, Hollander Z, Lam KK et al. Association of serum MiR-142-3p and MiR-101-3p levels with acute cellular rejection after heart transplantation. PLoS ONE 12(1), e0170842 (2017).
21. Duong Van Huyen J-P, Tible M, Gay A et al. MicroRNAs as non-invasive biomarkers of heart transplant rejection. Eur. Heart J. 35(45), 3194-3202 (2014).
22. Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 24(11), 1710-1720 (2005).
23. Berry GJ, Burke MM, Andersen C et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 32(12), 1147-1162 (2013).
24. Halloran PF, Reeve JP, Pereira AB, Hidalgo LG, Famulski KS. Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: New insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int. 85(2), 258-264 (2014).
25. Loupy A, Lefaucheur C, Vernerey D et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J. Am. Soc. Nephrol. 25(10), 2267-2277 (2014).
26. Mengel M, Sis B, Kim D et al. The molecular phenotype of heart transplant biopsies: Relationship to histopathological and clinical variables. Am. J. Transplant. 10(9), 2105-2115 (2010).
27. Hammond EH, Yowell RL, Nunoda S et al. Vascular (humoral) rejection in heart transplantation: Pathologic observations and clinical implications. J. Heart Transplant. 8(6), 430-443 (1989).
28. Kobashigawa J, Crespo-Leiro MG, Ensminger SM et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 30(3), 252-269 (2011).
29. Afzali B, Chapman E, Racapé M et al. Molecular assessment of microcirculation injury in formalin-fixed human cardiac allograft biopsies with antibody-mediated rejection. Am. J. Transplant. 17(2), 496-505 (2016).
30. Loupy A, Duong Van Huyen J-P, Hidalgo L et al. Gene expression profiling for the identification and classification of antibody-mediated heart rejection. Circulation 135(10), 917-935 (2017).